Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type

Snider, B. Joy; Roe, Catherine M.; Shah, Aarti R.; Grant, Elizabeth; Xiong, Chengjie; Morris, John C.; Holtzman, David M.

doi:10.1001/archneurol.2009.55

Cited by 208 publications

(124 citation statements)

References 40 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…A study with a protracted clinical follow-up period has revealed that the combination of all three core CSF biomarkers shows a sensitivity of 95% to recognize prodromal AD in MCI [76]. Moreover, these markers are able to predict the rate of cognitive decline in patients with MCI/very mild AD dementia [77].…”

Section: Prodromal Admentioning

confidence: 99%

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel

Lista

Teipel

et al. 2014

Biochemical Pharmacology

102

View full text Add to dashboard Cite

Recent advances in understanding the molecular mechanisms underlying various paths toward the pathogenesis of Alzheimer's disease (AD) has begun to provide new insight for interventions to modify disease progression. The evolving knowledge gained from multidisciplinary basic research has begun to identify new concepts for treatments and distinct classes of therapeutic targets; as well as putative disease-modifying compounds that are now being tested in clinical trials. There is a mounting consensus that such disease modifying compounds and/or interventions are more likely to be effectively administered as early as possible in the cascade of pathogenic processes preceding and underlying the clinical expression of AD. The budding sentiment is that "treatments" need to be applied before various molecular mechanisms converge into an irreversible pathway leading to morphological, metabolic and functional alterations that characterize the pathophysiology of AD. In light of this, biological indicators of pathophysiological mechanisms are desired to chart and detect AD throughout the asymptomatic early molecular stages into the prodromal and early dementia phase. A major conceptual development in the clinical AD research field was the recent proposal of new diagnostic criteria, which specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD. This paradigm shift in AD definition, conceptualization, operationalization, detection and diagnosis represents novel fundamental opportunities for the modification of interventional trial designs. This perspective summarizes not only present knowledge regarding biological markers but also unresolved questions on the status of surrogate indicators for detection of the disease in asymptomatic people and diagnosis of AD

show abstract

Section: Prodromal Admentioning

confidence: 99%

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel

Lista

Teipel

et al. 2014

Biochemical Pharmacology

102

View full text Add to dashboard Cite

show abstract

“…In this regard, a combination of high CSF tau without proportionally elevated p-tau-181 is associated with a faster rate of cognitive decline [147]. In this regard, longitudinal studies indicates that a combination of low Aβ42 and high tau and p-tau levels is highly predictive of MCI progression and cognitive decline rate [74,148].…”

Section: Phospho-taumentioning

confidence: 99%

“…Firstly, their appropriate sensibility and sensitivity have been successfully validated by independent large-scale multicentre studies [65][66][67][68][69], although these studies also point out that biomarkers measurements present significant inter-laboratory variations [70]. Secondly, Aβ42, tau and p-tau have been validated as predictors of AD in patients with MCI [71][72][73][74]. Lastly, longitudinal studies indicate that, at least, Tau and Aβ42 in CSF reflect the underlying disease state in early clinical and late stages of AD.…”

Section: Protein Biomarkersmentioning

confidence: 99%

New Frontiers in Alzheimer's Disease Diagnosis

Llorens¹,

Nuhn²,

Peter³

et al. 2015

Alzheimer's Disease - Challenges for the Future

View full text Add to dashboard Cite

“…Although some well-characterized biomarkers (e.g., tau protein and amyloid-␤42 in cerebrospinal fluid) and sophisticated neuroimaging instruments [e.g., magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET)] have been shown to reliably detect early AD pathology [17], there are still some significant limitations to these approaches, such as low to moderate sensitivity and specificity of preclinical measurements, high costs, invasiveness, need of radioactive tracers, and the absence of standardization and clear diagnostic cutoff values [17][18][19]. Several reports over the past decade described the potential diagnostic importance of electrophysiological markers of cognitive decline in patients with MCI and the preclinical stage of AD, as obtained by analysis of the electroencephalography-derived event-related potentials (ERPs) [20][21][22][23][24][25][26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

The Role of Physical Fitness in the Neurocognitive Performance of Task Switching in Older Persons with Mild Cognitive Impairment

Tsai

Pai

Ukropec

et al. 2016

JAD

View full text Add to dashboard Cite

Abstract. Although elderly people with amnestic mild cognitive impairment (aMCI) have been found to show impaired behavioral performance in task switching, no research has yet explored the electrophysiological mechanisms and the potential correlation between physical fitness and neurocognitive (i.e., behavioral and electrophysiological) performance in aMCI. The present study was thus aimed to examine whether there are differences in electrophysiological (i.e., event-related potential) performance between aMCI participants and controls when performing a task-switching paradigm, and to investigate the role of physical fitness in the relationship between neurocognitive performance and aMCI. Sixty participants were classified into aMCI (n = 30) and control (n = 30) groups, and performed a task-switching paradigm with concomitant electrophysiological recording, as well as underwent senior functional physical fitness tests. The aMCI group showed comparable scores on most parts of the physical fitness tests, but reduced lower body flexibility and VO 2max as compared to the control group. When performing the task-switching paradigm, the aMCI group showed slower reaction times in the heterogeneous condition and larger global switching costs, although no significant difference was observed in accuracy rates between the two groups. In addition, the aMCI group showed significantly prolonged P3 latencies in the homogeneous and heterogeneous conditions, and a smaller P3 amplitude only in the heterogeneous condition. The level of cardiorespiratory fitness was significantly correlated with P3 amplitude in the aMCI group, particularly in the heterogeneous condition of the task-switching paradigm. These results show that the aMCI group exhibited abnormalities in their neurocognitive performance when performing the task-switching paradigm and such a deficit was likely associated with reduced cardiorespiratory fitness, which was shown to be the important predictor of neurocognitive performance.

show abstract

Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type

Cited by 208 publications

References 40 publications

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

New Frontiers in Alzheimer's Disease Diagnosis

The Role of Physical Fitness in the Neurocognitive Performance of Task Switching in Older Persons with Mild Cognitive Impairment

Contact Info

Product

Resources

About